3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Conditions
Glioblastoma
5
Neoplasms
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Gliosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
29
Bevacizumab
14
Radiotherapy
12
Trastuzumab
10
Lomustine
9
Capecitabine
8
paclitaxel-Angiopep-2 conjugate
6
Nivolumab
6
pembrolizumab
5
dabrafenib
5
abemaciclib
5
Radiation
5
icotinib
4
Surgical Procedures, Operative
4
Paclitaxel
4
Lapatinib
4
Irinotecan
4
Flucytosine
4
Dianhydrogalactitol
4
Corticotropin-Releasing Hormone
4
Chlorotoxin
4
Carboplatin
4
vocimagene amiretrorepvec
3
verubulin
3
tucatinib
3
osimertinib
3
motexafin gadolinium
3
XL647
3
Spermine Synthase
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Brain Neoplasms
×
depatuxizumab mafodotin
×
Clear all
NCT02573324
2023-05-11
Intellance1
AbbVie
Phase 3
Completed
691 enrolled
28 charts
NCT02343406
2020-05-22
INTELLANCE-2
AbbVie
Phase 2
Completed
266 enrolled
23 charts